Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer (vol 34, pg 3740, 2016)

被引：0
|
作者：
Reck
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 34期
关键词：
D O I：
10.1200/JCO.19.02803
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3327 / 3327
页数：1
相关论文
共 50 条
  • [41] Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer
    Zheng-tao Zhou
    Fu-xiang Zhou
    Qing Wei
    Li-yong Zou
    Bin-fang Qin
    Xu-shen Peng
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1027 - 1032
  • [42] A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)
    Horn, L.
    Reck, M.
    Mok, T. S. K.
    Johnson, M.
    Waterkamp, D.
    Lam, S.
    Tang, X.
    Sandler, A.
    Lopez-Chavez, A.
    Giaccone, G.
    Liu, S. V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with extensive disease small cell lung cancer
    Schmittel, A.
    Fischer von Weikersthal, L.
    Sebastian, M.
    Schulze, K.
    Link, H.
    Thiel, E.
    Keilholz, U.
    EJC SUPPLEMENTS, 2005, 3 (02): : 327 - 328
  • [44] Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: A randomized phase II trial.
    Schmittel, A
    von Weikersthal, LF
    Sebastian, M
    Link, H
    Schulze, K
    Thiel, E
    Keilhoz, U
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 632S - 632S
  • [45] Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
    Hanna, N
    Bunn, PA
    Langer, C
    Einhorn, L
    Guthrie, T
    Beck, T
    Ansar, R
    Ellis, P
    Byrne, M
    Morrison, M
    Hariharan, S
    Wang, B
    Sandler, A
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) : 2038 - 2043
  • [46] Randomized, phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated, extensive-stage, small-cell lung cancer (SCLC)
    Langer, C
    Hanna, N
    Einhorn, L
    Sandler, A
    Ansari, R
    Ellis, R
    Byrne, M
    Green, M
    Morrison, M
    Bunn, P
    LUNG CANCER, 2005, 49 : S53 - S54
  • [47] Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
    Noda, W
    Nishiwaki, Y
    Kawahara, M
    Negoro, S
    Sugiura, T
    Yokoyama, A
    Fukuoka, M
    Mori, K
    Watanabe, K
    Tamura, T
    Yamamoto, S
    Saijo, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02): : 85 - 91
  • [48] Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer
    Reck, M
    von Pawel, J
    Macha, HN
    Kaukel, E
    Deppermann, KM
    Bonnet, R
    Ulm, K
    Hessler, S
    Gatzemeier, U
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (15) : 1118 - 1127
  • [49] Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
    Owonikoko, Taofeek K.
    Dahlberg, Suzanne E.
    Sica, Gabriel L.
    Wagner, Lynne, I
    Wade, James L., III
    Srkalovic, Gordan
    Lash, Bradley W.
    Leach, Joseph W.
    Leal, Ticiana B.
    Aggarwal, Charu
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 222 - +
  • [50] Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate placebo in extensive-stage small-cell lung cancer: A North Central cancer treatment group study
    Rowland, KM
    Loprinzi, CL
    Shaw, EG
    Maksymiuk, AW
    Kuross, SA
    Jung, SH
    Kugler, JW
    Tschetter, LK
    Ghosh, C
    Schaefer, PL
    Owen, D
    Washburn, JH
    Webb, TA
    Mailliard, JA
    Jett, JR
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 135 - 141
12345